Skip to main content

ICH Q10 Pharmaceutical quality system (EMA/CHMP/ICH/214732/2007)

 ICH Q10, titled "Pharmaceutical Quality System" (EMA/CHMP/ICH/214732/2007), is a guideline developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). This guideline provides recommendations on establishing a pharmaceutical quality system (PQS) within the pharmaceutical industry to ensure the consistent production of high-quality pharmaceutical products. Here's an elaboration of ICH Q10:


1. Purpose of ICH Q10:

The primary purpose of ICH Q10 is to provide a harmonized framework for the implementation of a quality management system in pharmaceutical manufacturing. It emphasizes the importance of a proactive and integrated approach to quality assurance and regulatory compliance.

2. Scope:

ICH Q10 applies to the pharmaceutical quality system used throughout the product lifecycle, from product development and technology transfer to manufacturing, distribution, and post-marketing activities.

3. Core Principles:

ICH Q10 outlines a set of core principles that should guide the development and operation of the pharmaceutical quality system. These principles include a focus on patient safety, product quality, risk management, and a lifecycle approach to quality.

4. Quality Management System (QMS):

The guideline emphasizes the establishment and maintenance of a robust quality management system (QMS) that covers all aspects of pharmaceutical operations. The QMS should include policies, procedures, processes, and responsibilities related to quality.

5. Pharmaceutical Quality System Elements:

ICH Q10 defines several key elements of the pharmaceutical quality system, including quality risk management, a product quality review (PQR) system, process performance and product quality monitoring, and management of outsourced activities.

6. Risk Management:

The guideline encourages the systematic application of quality risk management (QRM) principles throughout the product lifecycle. Risk assessments should be conducted to identify, evaluate, and control risks to product quality and patient safety.

7. Change Management:

ICH Q10 emphasizes the importance of change management within the pharmaceutical quality system. Changes to processes, procedures, and specifications should be assessed for their impact on product quality and regulatory compliance.

8. Continual Improvement:

A culture of continual improvement is promoted in ICH Q10. Pharmaceutical companies are encouraged to monitor and analyze data, learn from deviations and non-conformities, and take corrective and preventive actions to enhance their quality systems.

9. Regulatory Expectations:

Regulatory authorities expect pharmaceutical companies to have a well-defined pharmaceutical quality system in place. Compliance with ICH Q10 is typically required during regulatory inspections and is a key aspect of demonstrating good manufacturing practices (GMP).

10. Documentation:

- Comprehensive documentation is essential within the pharmaceutical quality system. Manufacturers should maintain records of quality-related activities, including risk assessments, change control, and PQRs.

11. Training and Competency:

- Personnel involved in the pharmaceutical quality system should receive appropriate training and possess the necessary competence to carry out their roles effectively.

12. Lifecycle Approach:

- ICH Q10 promotes a lifecycle approach to product quality. Manufacturers should consider quality aspects from product development through commercialization and post-marketing, ensuring ongoing product quality.


In summary, ICH Q10 provides a structured framework for the establishment and maintenance of a pharmaceutical quality system that ensures the consistent production of high-quality pharmaceutical products. Compliance with this guideline helps pharmaceutical companies proactively manage risks, maintain regulatory compliance, and continuously improve their quality systems to benefit patients and consumers

Popular posts from this blog

Ago2 Immunoprecipitation for RISC-siRNA Quantitation

 Ago2 (Argonaute 2) immunoprecipitation (IP) is a technique used to isolate RNA-induced silencing complexes (RISC) from cell lysates. This method allows for the specific enrichment of active RISC complexes bound to small interfering RNA (siRNA) or microRNA (miRNA) within cells. By isolating these complexes, researchers can then quantify the siRNA associated with Ago2, which is an essential step in determining the efficacy of RISC loading and siRNA activity. Here’s a detailed overview of how Ago2 immunoprecipitation is performed for RISC-siRNA quantitation: Steps in Ago2 Immunoprecipitation for RISC-siRNA Quantitation Cell Lysis and Preparation of Lysate : Sample Preparation : Collect cells that have been treated with siRNA, then wash them with cold phosphate-buffered saline (PBS) to remove extracellular contaminants. Lysis : Lyse the cells in a gentle, RNA-preserving lysis buffer that typically includes detergents (e.g., NP-40 or Triton X-100), protease inhibitors, and RNase inhibi...
Read more

Guideline on development and manufacture of lentiviral vectors (CHMP/BWP/2458/03)

The guideline with the reference number "CHMP/BWP/2458/03" pertains to the "Guideline on Development and Manufacture of Lentiviral Vectors." This guideline was developed by the Committee for Medicinal Products for Human Use (CHMP) and the Biotechnology Working Party (BWP) of the European Medicines Agency (EMA). It provides recommendations and regulatory guidance for the development and manufacture of lentiviral vectors, which are widely used in gene therapy and cell therapy applications. Here's an overview of the key points covered in this guideline: 1. Introduction: The guideline begins with an introduction highlighting the increasing importance of lentiviral vectors in advanced therapies and the need for guidance on their development and manufacture. 2. Scope: It defines the scope of the guideline, which covers the development and manufacture of lentiviral vectors intended for use in gene therapy and cell therapy products for human use. 3. Quality and Characte...
Read more

Stem-Loop PCR for siRNA

 Stem-loop PCR is a method often used for detecting and quantifying small RNAs, such as siRNA or miRNA, which are typically difficult to amplify directly due to their short lengths. The method involves the design of a stem-loop reverse transcription (RT) primer, which enhances specificity and stability of the short RNA during the RT-PCR process, allowing for sensitive detection and quantification of the siRNA. Here’s a detailed guide to how stem-loop PCR can be applied to siRNA detection: Key Steps in Stem-Loop PCR for siRNA Designing the Stem-Loop RT Primer : Structure : The stem-loop RT primer consists of a loop region flanked by complementary sequences on either side (the "stem"), which will fold back on itself to form a hairpin structure. Specific Binding Region : A short sequence complementary to the 3’ end of the siRNA is added at the end of the stem-loop primer to ensure specific binding to the siRNA target. Stabilization : The loop structure helps prevent primer-dimer...
Read more

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more